Xerostomia Therapeutics Market Research 2026: Market Size, Trends, Segments And Growth Forecast
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
#Xerostomia Therapeutics Market Growth From $2.35 Billion In 2026 To $2.78 Billion By 2030 At A CAGR Of 4.3%#_x000D_
The xerostomia therapeutics market has shown consistent expansion over recent years. Its valuation is set to increase from $2.24 billion in 2025 to $2.35 billion in 2026, advancing at a compound annual growth rate (CAGR) of 5.0%. The market’s historical growth can be attributed to an aging population, the extensive use of xerogenic drugs, a rise in the prevalence of chronic diseases, heightened dental awareness, and hospital-based symptom management._x000D_
_x000D_
The xerostomia therapeutics market is projected to experience consistent expansion over the coming years, reaching $2.79 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.3%. This projected growth during the forecast period is due to factors such as increased availability of OTC products, a rise in side effects from cancer therapies, growing self-medication behaviors, an expanding network of pharmacies, and a greater emphasis on treatments that enhance quality of life. Key developments anticipated in this period include a surge in medication-induced dry mouth cases, increasing demand for over-the-counter remedies, wider acceptance of artificial saliva products, the growth of retail and mail-order pharmacies, and a heightened focus on managing oral symptoms._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Xerostomia Therapeutics Market Growth Drivers: What’s Behind The Acceleration?#_x000D_
The xerostomia therapeutics market is anticipated to expand due to the increasing occurrence of chronic diseases. These are enduring medical conditions that last for extended periods, typically advancing gradually and necessitating continuous care. The growing incidence of chronic ailments largely stems from inactive lifestyles, as insufficient physical activity leads to issues such as obesity, heart conditions, diabetes, and other persistent health problems. Xerostomia treatments assist individuals with chronic diseases by relieving dry mouth discomfort and enhancing oral hygiene, nutritional intake, and medication compliance, all of which are crucial for managing long-term health issues. For example, data from June 2024, provided by the National Health Service, a UK government department, revealed that 3,615,330 patients registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state of elevated blood sugar not yet classified as diabetes) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the rising burden of chronic diseases is propelling the growth of the xerostomia therapeutics market._x000D_
_x000D_
#Xerostomia Therapeutics Market Segment Landscape: Which Areas Lead Development?#_x000D_
The xerostomia therapeutics market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants_x000D_
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets_x000D_
3) By End-User: Adult, Pediatric_x000D_
_x000D_
Subsegments:_x000D_
1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes _x000D_
2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges_x000D_
_x000D_
#Xerostomia Therapeutics Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_
Companies operating significantly in the xerostomia therapeutics market are concentrating on patient-friendly, non-invasive treatment options, such as oral sprays, which provide targeted topical lubrication and a protective barrier coverage throughout the mouth to ease dry-mouth symptoms and support oral well-being. Oral sprays designed for xerostomia are formulations applied as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), either forming a hydrating film or a lipid-based coating to reduce moisture evaporation, enhance lubrication during chewing, swallowing, and speaking, and deliver extended relief to patients experiencing dry mouth. As an illustration, in July 2023, K Pharmaceuticals, a pharmaceutical company based in the US, launched Aquoral, a clinically-proven oral spray for managing xerostomia. This product utilizes patented Oxidized Glycerol Triesters (OGT) lipid technology to create a long-lasting protective barrier over the oral cavity, providing relief for up to six hours with just two quick sprays, which lessens the requirement for frequent reapplication compared to aqueous-based treatments._x000D_
_x000D_
#Xerostomia Therapeutics Market Industry Leaders And Competitive Landscape#_x000D_
Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd. _x000D_
_x000D_
#View The Full Xerostomia Therapeutics Market Report:#_x000D_
_x000D_
#Xerostomia Therapeutics Market Regional Analysis: Which Geography Leads On Revenue?#_x000D_
North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
